uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
186 articles with uniQure
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 13, 2023
3/13/2023
uniQure N.V. today announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment.
-
uniQure to Participate in Multiple Upcoming Industry Conferences in March
3/2/2023
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences.
-
In its 2022 financial report Monday, uniQure provided updates on the progress of its Huntington’s disease and ALS programs.
-
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
2/27/2023
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2022 and highlighted recent progress across its business.
-
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
2/23/2023
uniQure N.V. announced that its partner, global biotechnology leader CSL (ASX: CSL) today announced the publication in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8) of results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb).
-
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
2/21/2023
uniQure N.V. (NASDAQ: QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received conditional marketing authorization (CMA) from the European Commission for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B.
-
uniQure inked a deal with Apic Bio to gain development and commercialization rights to APB-102, a gene therapy for a rare, genetic form of ALS.
-
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
1/31/2023
uniQure N.V. and Apic Bio today announced that they have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare, genetic form of ALS.
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/20/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment.
-
uniQure announces positive CHMP opinion for etranacogene dezaparvovec
12/16/2022
uniQure N.V. announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogene dezaparvovec from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
-
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
11/29/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epilepsies.
-
BMS is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.
-
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
11/22/2022
uniQure N.V. (NASDAQ: QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received approval from the U.S. Food and Drug Administration (FDA) for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.
-
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
11/17/2022
uniQure N.V. today announced that it will host a Virtual Research & Development Event on Tuesday, November 29, 2022 from 8:30 a.m. to 10:30 a.m. EST.
-
A Data Safety Monitoring Board overseeing the Phase Ib/II trial assessing UniQure's gene therapy for Huntington's disease recommended that enrollment in the higher-dose cohort could resume.
-
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/2/2022
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the third quarter of 2022 and highlighted recent progress across its business.
-
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
8/8/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2022 and highlighted recent progress across its business.
-
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company's president of R&D, Dr. Ricardo Dolmetsch.
-
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
-
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
6/23/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.